ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arrowhead Pharmaceuticals Inc (ARWR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its obesity pipeline and analysts have raised price targets, the technical indicators do not show a strong upward trend, and the options data suggests bearish sentiment. Additionally, the company's financial performance shows a significant drop in net income and EPS despite a massive revenue increase, indicating potential profitability concerns. For a beginner investor, it may be better to monitor the stock for stronger technical signals or improved financial performance before committing.
The MACD is below 0 and negatively contracting, indicating a lack of bullish momentum. RSI is neutral at 48.46, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 63.276, with resistance at 65.073 and support at 61.479.
Analysts have raised price targets significantly, with some highlighting the potential of Arrowhead's obesity pipeline and RNAi platform. The company has promising Phase 1/2a data for its obesity candidates, which could drive long-term growth.
The options data reflects bearish sentiment, and the technical indicators do not show a strong upward trend. Financial performance shows a significant decline in net income and EPS despite a massive revenue increase, raising concerns about profitability. No recent congress trading data or influential figure activity is available to support confidence in the stock.
In Q1 2026, revenue increased by 10461.32% YoY to $264.03 million, but net income dropped by -117.80% YoY to $30.81 million, and EPS fell by -115.83% YoY to 0.22. Gross margin remained at 100%. While revenue growth is impressive, the decline in profitability is a concern.
Analysts have mixed views. While firms like B. Riley and H.C. Wainwright have raised price targets to $100 and $101, respectively, citing promising obesity pipeline data, Morgan Stanley maintains an Equal Weight rating with a lowered price target of $78. The stock is seen as undervalued by some analysts, but others are cautious about near-term sales growth.
